Replies to post #160365 on Biotech Values

[jq1234]

It seems even newer candidates with more selective S1PR still have similar CV profile as Gilenya. Gilenya is not doing that bad with 1Q revenue of $421m.

[mcbio]

RCPT

The name of the game is more selective S1PR agonists with improved safety profile compared to the 1st gen - Gilenya and I think so far they are all hitting bumps and the S1P system is not sufficiently understood.

Thanks very much for the detailed response. Is RCPT's drug primarily just limited to potentially improving upon the safety of Gilenya or is there the potential for it to improve upon efficacy as well? Ideally, I'd hope there be potential for improvements in both.